Tags

Type your tag names separated by a space and hit enter

Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.
Int Rev Neurobiol. 2010; 95:73-118.IR

Abstract

Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and L-dopa. When combined with decarboxylase inhibitor L-dopa is the most efficacious treatment for Parkinson's disease. Bioavailability and efficacy of L-dopa treatment can be enhanced greatly by the use of COMT inhibitors. This has been the driving force for development of new selective and potent COMT inhibitors. The success in COMT inhibitor development has generated a tremendous scientific interest in the role of COMT in health and disease. COMT inhibitors have also helped to clarify the reaction mechanism of COMT, increased interest in its structural biology, and physicochemical properties in order to develop even better COMT inhibitors. New techniques, especially the transgenic mice, have revealed further new aspects about the role of COMT in periphery as well as in the brain.

Authors+Show Affiliations

Orion Pharma, Research Center, Espoo, Finland.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21095460

Citation

Nissinen, Erkki, and Pekka T. Männistö. "Biochemistry and Pharmacology of catechol-O-methyltransferase Inhibitors." International Review of Neurobiology, vol. 95, 2010, pp. 73-118.
Nissinen E, Männistö PT. Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. Int Rev Neurobiol. 2010;95:73-118.
Nissinen, E., & Männistö, P. T. (2010). Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. International Review of Neurobiology, 95, 73-118. https://doi.org/10.1016/B978-0-12-381326-8.00005-3
Nissinen E, Männistö PT. Biochemistry and Pharmacology of catechol-O-methyltransferase Inhibitors. Int Rev Neurobiol. 2010;95:73-118. PubMed PMID: 21095460.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. AU - Nissinen,Erkki, AU - Männistö,Pekka T, PY - 2010/11/25/entrez PY - 2010/11/26/pubmed PY - 2011/3/8/medline SP - 73 EP - 118 JF - International review of neurobiology JO - Int Rev Neurobiol VL - 95 N2 - Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and L-dopa. When combined with decarboxylase inhibitor L-dopa is the most efficacious treatment for Parkinson's disease. Bioavailability and efficacy of L-dopa treatment can be enhanced greatly by the use of COMT inhibitors. This has been the driving force for development of new selective and potent COMT inhibitors. The success in COMT inhibitor development has generated a tremendous scientific interest in the role of COMT in health and disease. COMT inhibitors have also helped to clarify the reaction mechanism of COMT, increased interest in its structural biology, and physicochemical properties in order to develop even better COMT inhibitors. New techniques, especially the transgenic mice, have revealed further new aspects about the role of COMT in periphery as well as in the brain. SN - 2162-5514 UR - https://www.unboundmedicine.com/medline/citation/21095460/Biochemistry_and_pharmacology_of_catechol_O_methyltransferase_inhibitors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/B978-0-12-381326-8.00005-3 DB - PRIME DP - Unbound Medicine ER -